Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501182 | 0.80 | TSHR (0.44) | TSHRRGS12HSD17B10RBP4LMNA | |
| SCHEMBL2064738 | 0.78 | TSHR (0.42) | TSHRRGS12HSD17B10RBP4LMNA | |
| SCHEMBL2184430 | 0.76 | TSHR (0.50) | TSHRRGS12HSD17B10RBP4LMNA | |
| SCHEMBL5916254 | 0.74 | TSHR (0.39) | TSHRRGS12HSD17B10RBP4BACE1 | |
| Potassium Ion SCHEMBL16597641 | 0.74 | TSHR (0.44) | TSHRRGS12HSD17B10RBP4LMNA | |
| SCHEMBL16597486 | 0.74 | TSHR (0.44) | TSHRRGS12HSD17B10RBP4LMNA | |
| SCHEMBL16597743 | 0.74 | TSHR (0.44) | TSHRRGS12HSD17B10RBP4LMNA | |
| SCHEMBL17570777 | 0.74 | TSHR (0.40) | TSHRRGS12TDP1MAPK1 | |
| SCHEMBL11308612 | 0.73 | TSHR (0.38) | TSHRRGS12HSD17B10RBP4LMNA | |
| SCHEMBL8663025 | 0.71 | HSD17B10 (0.42) | TSHRRGS12HSD17B10LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | UNIVERSITY OF KANSAS (US) | 2010-04-29 | — | — | US | disclosed |
| US-4113950-A | PROCESS FOR PREPARING OROTIC ACID AND THIOOROTIC ACID | DIAMALT AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4062847-A | Process for preparing orotic acid | DIAMALT AKTIENGESELLSCHAFT (DT) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | SSB, IAPP, NLN | TSHR 3684/4885RGS12 3653/4885HSD17B10 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.